电脑桌面
添加小米粒文库到电脑桌面
安装后可以在桌面快捷访问

已上市化学药品变更研究的技术指导原则英文版VIP免费

已上市化学药品变更研究的技术指导原则英文版_第1页
1/76
已上市化学药品变更研究的技术指导原则英文版_第2页
2/76
已上市化学药品变更研究的技术指导原则英文版_第3页
3/76
HGB(1)T-1GUIDELINENo.:TechnicalGuidelineforMakingPostApprovalChangestoChemicalDrugProducts1April20082TableofcontentsI.Overview...........................................................................................................................2II.Basicprinciplesforperformingstudiespost-approvalchangestochemicaldrugproducts...............................................................................................................................3III.ChangestoDrugSubstanceManufacturingProcess.....................................................6IV.Changestoexcipientsinadrugformulation...............................................................14V.Changestothemanufacturingprocessforadrugproduct.........................................22VI.Changestodrugproductstrengthandpackagingsize..............................................30VII.Change............................................................todrugprodcugtspecificication36VIII.Changestothedrugprodcutshelf-life(expirationdatingperiod)and/orstorageconditions...........................................................................................................................41IX.Changestodrugproductpackagingmaterialsandthecontainerclosuresyatem...37X.Changestothemanufacturingsiteofanimporteddrugproduct...............................51XI.ChangetothemanufacturingsiteofAPIusedinanimporteddrugproductandchangetothemanufacturingsiteofanimportedAPI......................................................48XII.ChangesinthesiteofManufactureforAPIusedinadomesticdrugproduct.....Error!Bookmarknotdefined.AppendixIBasicmethodsforcomparisoninvestigationofdrugdissolution/release.....36AppendixIIGeneralconsiderationsforexemptionofinvivobioequivalence(BEwaiver)............................................................................................................................................72AppendixIIIApartiallistofofmedicineswithnarrowtherapeuticwindows............Error!Bookmarknotdefined.References.........................................................................................................................77Glossary.............................................................................................................................79Authors...............................................................................................................................801I.OverviewThisguidelineisprimarilyusedtoguidepharmaceuticalmanufacturerstocarryoutstudiesforpost-approvalchanges(orchanges)tochemicaldrugproducts.Changeshererefertothechangesthatinvolvesource,methods,controlconditionswithrespecttothemanufacture,quality-controlanduseconditionandrelatedareasforadrugproductthathasbeenapprovedformarketing.Thesechangesmayaffecttheproduct’ssafety,efficacyandqualitycontrollability.Thechangestudyherereferstothestudyandqualificationworktosupportaproposedchange.Atpresent,thechangesandchangestudiescoveredinthisguideline’sincludethefollowingareas:thechangestoAPI/drugsubstance(DS)manufacturingprocess,excipientforpharmaceuticaluseinformulationanditsmanufacturingprocess,registeredspecifications,strengths,shelflife(expirationdatingperiod),storageconditions,drugproductpackagingmaterialsandcontainerclosuresystem,theimporteddrugproductmanufacturingsite,manufacturingsiteofimportedAPI/DSorAPI/DSusedinimportdrugproduct...

1、当您付费下载文档后,您只拥有了使用权限,并不意味着购买了版权,文档只能用于自身使用,不得用于其他商业用途(如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利)。
2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。
3、如文档内容存在违规,或者侵犯商业秘密、侵犯著作权等,请点击“违规举报”。

碎片内容

已上市化学药品变更研究的技术指导原则英文版

确认删除?
VIP
微信客服
  • 扫码咨询
会员Q群
  • 会员专属群点击这里加入QQ群
客服邮箱
回到顶部